Skip to the page

Data / Drug companies / AbbVie Inc.

AbbVie Inc.: 124 products in the FDA NDC directory, labeler code 0074

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

AbbVie Inc. (labeler code 0074) lists 124 products in the FDA National Drug Code Directory, covering 23 finished drugs by generic name. By type: 91 prescription drugs, 28 drugs for further processing. Its main marketing category is new drug applications (NDA). The newest product started marketing on October 23, 2026.

The request: Watch AbbVie Inc. (FDA labeler code 0074): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
0074
Products in commercial distribution
124
Packages
190
Finished drugs by generic name
23
Prescription products
91
Over the counter products
0
Flagged as original packager
75 of 75 products that carry the flag
Started marketing in the last 12 months
17
Products with a marketing end date set
2
Earliest marketing start
March 10, 1983
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
New drug applications (NDA)6552.4%
Drugs for further processing2721.8%
Biologics (BLA)2419.4%
Bulk ingredients54%
Generic drugs (ANDA)21.6%
Export only10.8%

Products by type

TypeProductsShare
Prescription drugs9173.4%
Drugs for further processing2822.6%
Bulk ingredients54%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Levothyroxine sodium1244
Leuprolide acetate1216
Risankizumab-rzaa111
Adalimumab94
Divalproex sodium648
Tavapadon51
Paricalcitol413
Venetoclax41
Upadacitinib41
Atogepant31
Lopinavir and ritonavir34
Cyclosporine224
Elagolix21
Glecaprevir and pibrentasvir21
Ritonavir28
Telisotuzumab vedotin21
Sevoflurane29
Foscarbidopa/foslevodopa11
Pivekimab sunirine-pvzy11
Beractant11
Carbidopa and levodopa141
Elagolix and estradiol and norethisterone11
Aztreonam and avibactam11

Dosage forms

Dosage formProductsShare
Kit2923.4%
Tablet2721.8%
Tablet, film coated1310.5%
Injection, solution108.1%
Liquid75.6%
Capsule64.8%
Injection64.8%
Tablet, extended release64.8%
Tablet, delayed release64.8%
Powder32.4%
Injection, powder, lyophilized, for solution32.4%
Solution21.6%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Skyrizi0074-1084KitBiologics (BLA)October 23, 2026
Ubrogepant0074-6498TabletDrugs for further processingSeptember 29, 2026
Juvmo0074-6315TabletNew drug applications (NDA)September 25, 2026
Juvmo0074-6210TabletNew drug applications (NDA)September 25, 2026
Juvmo0074-6105TabletNew drug applications (NDA)September 25, 2026
Juvmo0074-6090KitNew drug applications (NDA)September 25, 2026
Juvmo0074-5925TabletNew drug applications (NDA)September 25, 2026
Divalproex sodium0074-7347Tablet, delayed releaseDrugs for further processingSeptember 22, 2026
Divalproex sodium0074-7346Tablet, delayed releaseDrugs for further processingSeptember 22, 2026
Divalproex sodium0074-7345Tablet, delayed releaseDrugs for further processingSeptember 22, 2026
Ubrogepant0074-6501TabletDrugs for further processingSeptember 9, 2026
Ibrutinib0074-2585TabletDrugs for further processingSeptember 1, 2026
Venetoclax0074-1137Tablet, film coatedDrugs for further processingJuly 13, 2026
Venetoclax0074-1087Tablet, film coatedDrugs for further processingJuly 13, 2026
Skyrizi0074-4059Injection, solutionBiologics (BLA)June 12, 2026
Decnupaz0074-0282Injection, powder, lyophilized, for solutionBiologics (BLA)May 27, 2026
Venetoclax0074-0598PowderDrugs for further processingApril 1, 2026
Skyrizi0074-8350InjectionBiologics (BLA)September 3, 2025
Skyrizi0074-8300InjectionBiologics (BLA)September 3, 2025
Emrelis0074-1055Injection, powder, lyophilized, for solutionBiologics (BLA)May 14, 2025
Emrelis0074-1044Injection, powder, lyophilized, for solutionBiologics (BLA)May 14, 2025
Risankizumab0074-5025Injection, solutionDrugs for further processingApril 4, 2025
Emblaveo0074-3878Powder, for solutionNew drug applications (NDA)February 7, 2025
Risankizumab0074-9011LiquidDrugs for further processingFebruary 4, 2025
Risankizumab0074-1078LiquidBulk ingredientsDecember 9, 2024

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.